Are you looking for the next big investment opportunity in the pharmaceutical industry? Look no further than Jazz Pharmaceuticals, a company that Goldman Sachs believes is a prime buying opportunity right now.
Goldman Sachs recently initiated coverage of Jazz Pharmaceuticals with a buy rating and set a 12-month price target of $169, implying a potential 62% upside from the current price of $104.48. Analyst Andrea Tan sees this as a great entry point for investors, as Jazz Pharmaceuticals has slipped 15% this year, creating a favorable buying opportunity.
While investors have expressed concerns about Jazz’s potential loss of exclusivity and increased competition in the oxybate market, Tan points out that the company’s overlooked pipeline could offset these losses. With upcoming catalysts in oncology and the strategic initiative Vision 2025, which aims to reach $5 billion in revenue by 2025, Jazz Pharmaceuticals has a promising future ahead.
Not only does Jazz Pharmaceuticals have a strong balance sheet and a history of consistent cash generation, but Tan also believes the company is well-positioned to make strategic investments in external innovation through mergers and acquisitions or business development.
At Extreme Investor Network, we believe that Jazz Pharmaceuticals presents a unique investment opportunity in the pharmaceutical sector. With a strong growth potential and a solid foundation, Jazz Pharmaceuticals could be the next big winner in your investment portfolio. Stay ahead of the curve and consider adding Jazz Pharmaceuticals to your investment watchlist today.